Management of corticosteroid-induced osteoporosis;Prise en charge de l'ostéoporose cortisonique

Presse Medicale

Volumn 35, Issue 10 II, 2006, Pages 1571-1577

  Orcel, Philippe ^a  

^a CENTRE VIGGO PETERSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; BONE DENSITOMETRY; CHEMOPROPHYLAXIS; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RHEUMATOLOGY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION;

EID: 33749615281     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74853-9     Document Type: Review

References (39)

1. Orcel P, Roux C. Ostéoporose cortisonique. Rev Rhum Ed Fr. 2001; 68: 678-84.
2. Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol. 2003; 58: 302-8.
3. Roux C, Orcel P. Prévention et traitement de l'ostéoporose cortisonique. Rev Med Int. 2003; 24: 384-8.
4. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996; 313: 344-6.
5. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000; 93: 105-11.
6. Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis. 1995; 54: 66-8.
7. Buckley LM, Marquez M, Hudson JO, Downs RW, Vacek P, Small RE et al. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 1998; 25: 2195-202.
8. Curtis JR, Allison J, Becker A, Casebeer L, George V, Kovac SH et al. Screening and treatment of glucocorticoid induced osteoporosis among 6517 adults. J Bone Miner Res. 2004; 19 (suppl 1): S30 (abstr 1114).
9. Soucy E, Bellamy N, Adachi JD, Pope JE, Flynn J, Sutton E et al. A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. J Rheumatol. 2000; 27: 1506-12.
10. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15: 993-1000.
11. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology. 2000; 39: 1383-9.
12. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48: 3224-9.
13. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998; 244: 271-92.
14. Van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005; 98: 191-8.
15. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994; 37: 1499-505.
16. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996; 125: 961-8.
17. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; 2: CD000952.
18. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res. 2000; 15: 754-62.
19. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999; 104: 1363-74.
20. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337: 382-7.
21. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab. 1998; 83: 1128-33.
22. Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol. 2000; 27: 2424-31.
23. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1999; 339: 292-9.
24. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44: 202-11.
25. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42: 2309-18.
26. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000; 15: 1006-13.
27. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000; 11: 331-7.
28. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67: 277-85.
29. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res. 2001; 16: 104-12.
30. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003; 14: 801-7.
31. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol. 1999; 26: 1148-57.
32. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000; 2: CD001347.
33. American College of Rheumatology Task Force on Osteoporosis guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996; 39: 1791-801.
34. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000; 29: 228-51.
35. Afssaps. Traitement médicamenteux de l'ostéoporose cortisonique. Recommandation de bonne pratique. 2003. http://agmed.sante.gouv. fr/htm/5/rbp/indrbp.htm.
36. ANAES. L'ostéoporose chez les femmes ménopausées et chez les sujets traités par corticoïdes : méthodes diagnostiques et indications. Recommandations et références professionnelles. 2001. http://www.has-sante.fr/anaes/anaesparametrage.nsf.
37. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104: 439-46.
38. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998; 102: 1627-33.
39. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999; 14: 1061-6.